TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
Home
Press release
Mar 24, 2023 13:22 JST
Source:
Eisai
Eisai to Present Research from Oncology Portfolio at The Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer
TOKYO, Mar 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of two abstracts at the Society of Gynecologic Oncology (SGO) 2023 Annual Meeting on Women's Cancer (#SGOMtg), which is taking place in-person in Tampa, Florida and virtually from March 25-28.
Notable research to be featured in the Scientific Plenary IX: The Best of the Rest session includes a presentation of real-world outcomes and healthcare resource utilization in patients with recurrent or advanced endometrial carcinoma who were rechallenged with platinum chemotherapy in Europe (Abstract: #17). Also to be presented are data from the LEAP (LEnvatinib And Pembrolizumab) clinical program analyzing tumor-response from the lenvatinib (LENVIMA) plus pembrolizumab (KEYTRUDA) arm of the pivotal Phase 3 Study 309/KEYNOTE-775 trial in patients with advanced endometrial carcinoma following at-least one prior platinum-based regimen in any setting (NCT03517449; Abstract: #518).
"We look forward to sharing our data at this year's SGO Annual Meeting, particularly a new study that will be presented in an oral scientific plenary session featuring real-world outcomes in patients with recurrent or advanced endometrial cancer who were rechallenged with platinum chemotherapy," said Dr. Takashi Owa, Chief Scientific Officer, Senior Vice President, Eisai Co., Ltd. "We believe this research is important to the healthcare providers and patients we aim to serve because it is essential to understand treatment dynamics and related outcomes in clinical practice. As a human health care company, we remain steadfast in our commitment to advance the science of cancer medicine through the generation of real-world evidence."
In March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada), through an affiliate, entered into a strategic collaboration for the worldwide co-development and co-commercialization of lenvatinib, both as monotherapy and in combination with Merck's anti-PD-1 therapy pembrolizumab. To date, more than 10 trials have been initiated under the LEAP clinical program, which is evaluating the combination across multiple tumor types.
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
For more information, visit www.eisai.com/news/2023/news202322.html.
Media Inquiries:
Public Relations Department,
Eisai Co., Ltd.
+81-(0)3-3817-5120
Source: Eisai
Sectors: BioTech
Copyright ©2024 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Related Press Release
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
September 05 2024 15:59 JST
Eisai Announces Status Relating to Acquisition of Own Shares
September 02 2024 14:12 JST
Leqembi (lecanemab) Authorized for Early Alzheimer's Disease in Great Britain
August 22 2024 18:54 JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in the United Arab Emirates
August 14 2024 08:59 JST
Eisai: Update Regarding the Regulatory Status of LEQEMBI Subcutaneous Formulation
August 06 2024 12:15 JST
New Clinical Data Demonstrates Three Years of Continuous Treatment with Dual-Acting LEQEMBI (lecanemab-irmb) Continues to Significantly Benefit Early Alzheimer's Disease Patients Presented at AAIC 2024
July 31 2024 12:59 JST
Update on Regulatory Review of Lecanemab for Early Alzheimer's Disease in the European Union
July 29 2024 16:59 JST
Eisai and EcoNaviSta Enter into Business Alliance Agreement Aimed at Building a Dementia Ecosystem and Commence Collaboration
July 25 2024 09:30 JST
Eisai to Present Dual-Acting Lecanemab Three-Year Efficacy and Safety Data and Discuss Long-Term Outcomes of Continued Treatment at the Alzheimer's Association International Conference 2024
July 23 2024 19:23 JST
"LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in Israel
July 12 2024 11:56 JST
More Press release >>
Latest Press Release
TANAKA Precious Metals Announces Executive Appointments
Sep 07, 2024 03:00 JST
Panasonic Energy and Mazda to Begin Preparation for Supply of Automotive Lithium-ion Batteries
Sep 06, 2024 16:34 JST
Toyota's Next-Generation BEV Battery Development and Production Plan Certified by METI
Sep 06, 2024 15:10 JST
Toyota Motor Corporation and BMW Group Strengthen Collaboration Towards the Advancement of a Hydrogen Society
Sep 06, 2024 09:26 JST
DENSO Fukushima Launches Production of Inverters
Sep 05, 2024 17:41 JST
Eisai Accelerates Progress in Oncology Research with New Data at ESMO Congress 2024
Sep 05, 2024 16:59 JST
Launch of IOWN Network Solution for 400Gbps High-Speed Inter-Data Center Connections that Reduces Construction and Operation Costs by 50%, and power consumption by 40%
Sep 05, 2024 11:58 JST
Fujitsu and MoBagel revolutionize business processes through accelerated AI prediction
Sep 05, 2024 10:40 JST
Hitachi Develops a Model of BuilMirai Building IoT Solution for Small and Medium-Sized Buildings to Strengthen Green & Smart Building Business
Sep 04, 2024 12:22 JST
Seven Companies Announce to Conduct Engineering Design Work for Japanese Advanced CCS (Carbon Capture and Storage) Project
Sep 04, 2024 11:46 JST
MHI and Mitsubishi Logisnext to Display "SigmaSynX" Products Enabling Autonomous and Intelligent Warehouse Logistics
Sep 04, 2024 09:48 JST
Cisgenics Brings Next-Generation Irrigation Technology to Australia
Sep 03, 2024 13:29 JST
NEC Launches new system using Biometric Authentication Technology
Sep 03, 2024 10:38 JST
Terrific Texas fight back from TOYOTA GAZOO Racing
Sep 02, 2024 17:09 JST
Eisai Announces Status Relating to Acquisition of Own Shares
Sep 02, 2024 15:12 JST
TANAKA Memorial Foundation to Offer Precious Metals Research Grants of Up to 10 Million Yen (from a Grant Pool of 20 Million Yen)
Sep 02, 2024 11:00 JST
Fujitsu establishes Open All-Photonics Network Lab in Europe to promote global expansion of innovative network infrastructure
Aug 30, 2024 18:15 JST
JCB and Permata Launch the Permata JCB Ultimate Card
Aug 30, 2024 17:00 JST
JCB and BINDO Launch World's First Metal JCB Card
Aug 30, 2024 17:00 JST
Intercity Battery Train Starts Testing in the North of England
Aug 29, 2024 19:20 JST
More Latest Release >>